Pressure increases to finance MS drugs

By Lyn Whitfield1998-06-18T00:00:00

Health authorities could be under pressure to fund Betaferon treatment for thousands more patients - at a cost of millions of pounds - by the end of the year.

You need to be signed in to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All of HSJ.co.uk and our HSJ mobile app
News and insight on all areas of public funded healthcare
Expert commentary, insight and analysis from industry leaders
9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

to HSJ

Sign into your account here